Skip to search formSkip to main contentSkip to account menu

TG4010

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit… 
2017
2017
BackgroundAdvanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and… 
Review
2014
Review
2014
Non-small-cell lung cancer (NSCLC) is a highly prevalent and aggressive disease. In the metastatic setting, major advances… 
2012
2012
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as… 
Highly Cited
2010
Highly Cited
2010
MUC1 over-expression in renal clear-cell carcinoma (RCC) is associated with poor prognosis. This phase II study determined the… 
Highly Cited
2008
Highly Cited
2008
Background: TG4010 is a recombinant viral vector expressing both the tumor-associated antigen MUC1 and Interleukine-2. This… 
Highly Cited
2008
Highly Cited
2008
SummaryPurpose: TG4010 is a recombinant MVA vector expressing the tumor-associated antigen MUC1 and IL2. We explored the effect… 
Highly Cited
2003
Highly Cited
2003
The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin‐secreting epithelial cells in many…